Table 2.
Number and type of operations, risk assessment, and major post-operative complications progression following recommencement of surgery at both trust sites
| Period | March–May 2020 (n = 97) | June–August 2020 (n = 130) | p-value |
|---|---|---|---|
| Age, mean (SD) | 66.5 (13.5) | 67.4 (13.7) | 0.683 |
| Male | 66 (68%) | 89 (68.4%) | 0.74 |
| Ethnicity | |||
| White | 74 (76%) | 94 (72%) | 0.654 |
| Asian | 2 (2%) | 4 (3%) | 0.43 |
| Black | 2 (2%) | 4 (3%) | 0.231 |
| Other | 19 (20%) | 28 (22%) | 0.343 |
| Ischaemic heart disease | 17 (17.5%) | 20 (15.4%) | 0.245 |
| Chronic lung disease | 17 (17.5%) | 21 (16.2%) | 0.62 |
| Hypertension | 62 (63.9%) | 83 (63.8%) | 0.544 |
| Diabetes | 19 (19.6%) | 23 (17.7%) | 0.4 |
| Dyslipidaemia | 30 (30.9%) | 42 (32.3%) | 0.254 |
| Chronic kidney disease | 12 (12.3%) | 10 (7.6%) | 0.37 |
| Coagulopathy | 3 (3.1%) | 5 (3.8%) | 0.5 |
| Chronic liver disease | 2 (2.1%) | 3 (2.3%) | 0.661 |
| Malignancy | 1 (1%) | 2 (1.5%) | 0.225 |
| Type of operations | |||
| AVR | 52 | 61 | N/A |
| AVR + CABG | 15 | 18 | N/A |
| AVR + aortic | 17 | 29 | N/A |
| AVR + MVR | 3 | 8 | N/A |
| Multivalvular/complex | 10 | 14 | N/A |
| Euroscore II (median [IQR]) | 2.7 [1.9–5.2] | 2.8 [1.5–5.2] | 0.469 |
| Urgent/emergency setting | 57 (59%) | 57 (43%) | 0.026 |
| NYHA/CCS III/IV | 74 (76.3%) | 101 (77.7%) | 0.417 |
| Endocarditis | 11 (11.3%) | 16 (12.3%) | 0.55 |
| Re-do operations | 8 (8.2%) | 24 (18.4%) | 0.04 |
| 30-day mortality | 0 (0%) | 3 (2.3%) | 0.2 |
| Re-sternotomy for bleeding | 3 (3.1%) | 10 (7.7%) | 0.167 |
| TIA/stroke | 2 (2.1%) | 4 (3%) | 0.38 |
| New need for RRT | 9 (9.3%) | 7 (5.4%) | 0.178 |
| Pre-operative COVID-19 | 0 (0%) | 0 (0%) | 0.628 |
| Post-operative COVID-19 | 0 (0%) | 0 (0%) | 0.628 |